Equities Analysts Set Expectations for ABVX FY2024 Earnings

ABIVAX Société Anonyme (NASDAQ:ABVX) – Investment analysts at Leerink Partnrs dropped their FY2024 EPS estimates for shares of ABIVAX Société Anonyme in a report released on Tuesday, March 18th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($3.08) per share for the year, down from their prior estimate of ($2.93). The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.83) per share. Leerink Partnrs also issued estimates for ABIVAX Société Anonyme’s FY2025 earnings at ($3.00) EPS, FY2026 earnings at ($1.78) EPS, FY2027 earnings at ($1.09) EPS and FY2028 earnings at ($0.84) EPS.

A number of other equities research analysts have also weighed in on the stock. Citizens Jmp raised shares of ABIVAX Société Anonyme to a “strong-buy” rating in a research report on Wednesday, December 4th. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 price objective on shares of ABIVAX Société Anonyme in a research note on Thursday. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $33.00 target price on shares of ABIVAX Société Anonyme in a research report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, ABIVAX Société Anonyme presently has an average rating of “Buy” and an average price target of $38.00.

ABIVAX Société Anonyme Stock Up 3.2 %

ABIVAX Société Anonyme stock opened at $7.06 on Thursday. The firm’s fifty day moving average price is $6.71 and its two-hundred day moving average price is $8.59. ABIVAX Société Anonyme has a 1-year low of $5.50 and a 1-year high of $16.63.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Several hedge funds have recently modified their holdings of ABVX. Kennedy Capital Management LLC increased its position in shares of ABIVAX Société Anonyme by 0.7% during the fourth quarter. Kennedy Capital Management LLC now owns 225,470 shares of the company’s stock valued at $1,650,000 after acquiring an additional 1,656 shares during the last quarter. Bank of America Corp DE grew its stake in ABIVAX Société Anonyme by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after purchasing an additional 1,990 shares during the period. GAMMA Investing LLC purchased a new stake in shares of ABIVAX Société Anonyme during the 4th quarter valued at $29,000. R Squared Ltd bought a new stake in shares of ABIVAX Société Anonyme during the 4th quarter worth $36,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after buying an additional 5,900 shares during the last quarter. Institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.